Merial Introduces Oravet Dental Hygiene Chews for Dogs
Jul 10 15
Merial announced the launch in the U.S. of Oravet dental hygiene chews for dogs at the annual meeting of the American Veterinary Medical Association in Boston, Massachusetts. Oravet dental hygiene chews use exclusive, new, dual-action technology to significantly reduce the formation of plaque, calculus and halitosis at their source. Oravet dental hygiene chews provide a unique, easy-to-administer option designed to help pet owners comply with veterinary recommendations for at-home maintenance of their dogs' oral hygiene. Each Oravet dental hygiene chew releases delmopinol, an innovative compound originally developed for human dentistry and exclusively licensed to Merial for veterinary use. Delmopinol creates a barrier that prevents bacterial attachment to teeth, tongue and gingiva, inhibiting the production of biofilms that form plaque and the volatile sulfur compounds of halitosis. During chewing, the malleable, high-density treat also helps scrub away existing plaque and calculus. Oravet dental hygiene chews are highly palatable, and when taken daily, have shown a 53% reduction in halitosis, a 42% reduction in plaque and a 54% reduction in calculus compared to dry diet alone. The chews, which may be given to dogs over 6 months of age, will be offered in three sizes based on a dog's weight. They will be available through veterinarians only. Oravet dental hygiene chews join Merial's extensive product portfolio dedicated to preventing and managing major pet health issues, including Heartgard® Plus (ivermectin/pyrantel), for the prevention of heartworm disease, Frontline® Plus (fipronil + (S)-methoprene) and NexGard® (afoxolaner), for flea and tick control and protection, and a large range of pet vaccines.
Merial Appoints Fabian Kausche to Lead Global Research & Development
Jun 10 14
Merial announced that Fabian Kausche will be leading the company's global research and development (R&D) efforts, effective June 9, 2014. Dr. Kausche brings to the company a wide range of global experience in pharmaceutical and biological R&D and business leadership positions, at both human and animal health companies. Dr. Kausche joins Merial after 10 years at Novartis, where he was most recently global Head of R&D for Animal Health. As the new Global Head of R&D, Dr. Kausche will be based in Duluth, Ga., USA, with responsibility for advancing Merial's leadership in the discovery and development of innovative vaccines and therapies for companion and production animals. He will lead Merial's global R&D team, including more than 700 scientists and support staff at R&D sites around the world, to advance more than 50 projects currently in development for a variety of animal species. Fabian Kausche will be a member of the Merial Leadership Team and will report to Merial CEO Carsten Hellmann. He will also be a member of the Sanofi R&D Leadership Team.